Page last updated: 2024-11-12

thiomandelic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thiomandelic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10464709
CHEMBL ID3234727
SCHEMBL ID74366
MeSH IDM0409885

Synonyms (17)

Synonym
2-mercapto-2-phenylacetic acid
2-phenyl-2-sulfanylacetic acid
thiomandelic acid
4695-09-4
alpha-mercapto-alpha-phenylacetic acid
AKOS010616566
CHEMBL3234727 ,
SCHEMBL74366
mercaptophenylacetic acid
QYIGFZOHYGYBLX-UHFFFAOYSA-N
phenylthioglykolsaure
bdbm50271834
EN300-105718
HY-129629
2-phenyl-2-sulfanylaceticacid
CS-0107023
Z808230894

Research Excerpts

Overview

Thiomandelic acid is a simple, broad spectrum, and reasonably potent inhibitor of metallo-beta-lactamases.

ExcerptReferenceRelevance
"Thiomandelic acid is a simple, broad spectrum, and reasonably potent inhibitor of metallo-beta-lactamases, enzymes that mediate resistance to beta-lactam antibiotics. "( The inhibitor thiomandelic acid binds to both metal ions in metallo-beta-lactamase and induces positive cooperativity in metal binding.
Ababou, A; Barsukov, I; Bauer, R; Damblon, C; Jensen, M; Olsen, L; Papamicael, C; Roberts, GC; Schofield, CJ, 2003
)
2.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Metallo-beta-lactamase type 2Bacillus cereusIC50 (µMol)0.10000.10000.10000.1000AID1495013
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1495013Inhibition of recombinant Bacillus cereus BC2 expressed in Escherichia coli BL21 (DE3) cells using FC4-FC5 as substrate by fluorescence-based assay2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID1128918Inhibition of Bacillus cereus metallo-beta-lactamase BcII2014European journal of medicinal chemistry, Apr-09, Volume: 76The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
AID1495010Inhibition of recombinant bacterial NDM1 expressed in Escherichia coli BL21 (DE3) cells using FC5 as fluorogenic reporter substrate preincubated at 10 to 300 mins followed by substrate addition2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID1495014Inhibition of recombinant full-length bacterial His6-tagged VIM2 (27 to 266 residues) expressed in Escherichia coli BL21 (DE3) cells using FC4-FC5 as substrate by fluorescence-based assay2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID1495012Inhibition of recombinant bacterial IMP1 expressed in Escherichia coli BL21 (DE3) cells using FC4-FC5 as substrate by fluorescence-based assay2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID1495015Inhibition of Aeromonas hydrophila CphA using fluorogenic cephalosporin as substrate2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID1495011Inhibition of recombinant full-length bacterial His6-tagged SPM1 (29 to 276 residues) expressed in Escherichia coli BL21 (DE3) cells using FC4-FC5 as substrate by fluorescence-based assay2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]